Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.
0/5 보강
APA
Molica S, Allsup D (2026). Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.. Expert review of anticancer therapy, 26(3), 295-299. https://doi.org/10.1080/14737140.2025.2590674
MLA
Molica S, et al.. "Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.." Expert review of anticancer therapy, vol. 26, no. 3, 2026, pp. 295-299.
PMID
41231101 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- CLL17: Fixed-duration paradigms match continuous ibrutinib in frontline chronic lymphocytic leukemia.
- Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.
- Ibrutinib acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.
- Beyond progression-free survival (PFS): time to next treatment (TTNT) as a patient-centered metric of clinical benefit in chronic lymphocytic leukemia (CLL).
- Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Comparative evaluation of two NGS-based assays for somatic hypermutation analysis of IGHV genes in chronic lymphocytic leukemia.
- From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
- Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis.
- Longitudinal Whole-Exome Sequencing Identifies Clonal Hematopoiesis and Genomic Heterogeneity as a Predictor of Treatment Outcome in Patients with Newly Diagnosed, Elderly Chronic Lymphocytic Leukemia.
- Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies.
- Concurrent hepatic cirrhosis and chronic lymphocytic leukemia: a challenging coexistence: a case report.